Aqsa, Jamia Millia Islamia
Vaccination is the quickest and most effective way to protect against infectious diseases. It helps your body to recognize the specific pathogen and generate an immune response against it. Different vaccines have been developed against the causative agent of the current Covid-19 pandemic. These vaccines have undergone successful clinical trials and now are being administered to a large number of people.6
Some successfully developed Covid-19 vaccines are – Oxford-Zeneca, Pfizer, Moderna, Covaxin, Johnson and Johnson, SputnikV, etc. Some of them use the whole virus(unarmed), some of them use parts of the virus that trigger the immune system and some use the genetic material.
The AstraZeneca vaccine- AZD7442
AstraZeneca is a multinational pharmaceutical and biotechnology company. It is known for its development of the COVID-19 vaccine. The vaccine contains the genetic code of SARS-CoV-2 spike protein. So, when a patient gets administered the vaccine, the spike protein is produced in the body. The body now recognizes this protein as a foreign antigen and generates an immune response against it. When the person gets infected with the Covid virus, the body recognizes the spike protein and destroys the virus. In 2020, AstraZeneca, along with Oxford University, successfully developed the vaccine for the Covid-19 virus. The vaccine showed to be 90% effective when two doses of it are administered in the patients. This vaccine was approved in India in early 2021.
India approved the use of this vaccine. It is made in the Serum Institute of India under the brand name, Covishield. The European Medicines Agency also granted permission for the vaccine to be administered to people who are above 18 years of age. But by mid-march, some rare cases surfaced, in which people who were administered with this vaccine developed a rare condition of blood clots with lowered platelets. As a result of this, some European countries halted the use of the Astra-Zeneca vaccine.
Good results from the trials
A new vaccine developed by AstraZeneca has recently shown positive results. The vaccine AZD7442 is particularly developed for people who had already been exposed to the virus. AZD7442 is a combination of two different vaccines. The previous trials of the same vaccine were not satisfactory and showed only 33 percent of the result. But the new trial showed a great contentment result.
The vaccine trial included 5,197 participants, who had an increased risk of infection and have not been previously exposed to the virus. The participants showed a 77 percentage of reduced risk of developing the disease after the administration of the vaccine. AZD7442 is also believed to prevent the symptomatic Covid-19 infection quickly and effectively. It is also put forward that the drug could be used with other vaccines for people who need more protection. This vaccine shows a promising result and could be an important tool in developing a successful solution.
A promising solution
The only hope to end the current COVID-19 pandemic is the administration of vaccines. Several different vaccines have been introduced to us. These vaccines make the immune system to create antibodies to fight COVID-19 virus. AZD7442 could be a promising solution to the people who need more protection.
Also read: Ancestral brains of Arthropods revealed by new fossils
Reference:
- AstraZeneca hails trial results for COVID treatment. https://medicalxpress.com/news/2021-08-astrazeneca-hails-trial-results-covid.html
- The Corrosion Prediction from the Corrosion Product Performance
- Nitrogen Resilience in Waterlogged Soybean plants
- Cell Senescence in Type II Diabetes: Therapeutic Potential
- Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
- AI Literacy in Early Childhood Education: Challenges and Opportunities
One thought on “AstraZeneca Vaccine: Successful Clinical Trial results”